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Summary Mitogen-induced mammary cell growth is often accompanied by decreased levels of expression of
the p1g5erbB-2 protein. We have previously reported that oestrogen inhibits erbB-2 mRNA and protein
expression in breast cancer cells, while epidermal growth factor (EGF) treatment has been shown to decrease
pl85elbB-2 levels in normal mouse mammary epithelial cells. In the present work, we studied the effect of
oestrogen and EGF on erbB-2 expression in oestrogen-responsive breast cancer cells. We observed that both
oestrogen and EGF comparably down-regulated p185elbB-2 levels, while stimulating growth of T47D and
ZR75.1 cells. Oestrogens, but not EGF, concomitantly down-regulated erbB-2 mRNA. Run-on analysis
showed a reduced erbB-2 transcription rate in the presence of oestrogens. Furthermore, the transcriptional
activity of a 219 bp proximal fragment of the human erbB-2 promoter was repressed by oestrogens, whereas it
was enhanced by EGF. EGF stimulated both tyrosine phosphorylation and autokinase activity of p185erbB-2
We conclude that oestrogens, but not EGF, inhibit erbB-2 expression by transcriptional repression, while EGF
down-regulates pl85elbB2 at a post-translational level. Thus, two factors converging in terms of effects on cell
growth, display divergent mechanisms of regulation of erbB-2 expression.
The erbB-2 oncogene encodes a 185 kDa tyrosine kinase
receptor (pl85erbB-2) with homology to the EGF receptor
(EGFR) (Yamamoto et al., 1986). p185erbB2, most likely in
heterodimeric arrangements with the proteins encoded by the
related genes erbB-3 and erbB-4 (Plowman et al., 1993; Sliw-
kowski et al., 1994), may constitute a receptor for the
recently described family of peptides named heregulins,
NDF, GGF and ARIA (reviewed by Mudge, 1993).
erbB-2 activation is frequent in human cancer. erbB-2 is
amplified in 20-25% of primary breast tumours (Slamon et
al., 1987; Berger et al., 1988; Adnane et al., 1989) and
overexpression of p185erbB-2 generally correlates with
unfavourable clinical outcome (reviewed by Perren, 1991;
Hynes, 1993). In most cases, erbB-2 overexpression is due to
gene amplification; however, the amount of erbB-2 mRNA or
pl85erbB-2 measured in some primary tumours and breast
cancer cell lines does not directly reflect erbB-2 gene copy
number (Kraus et al., 1988; Hynes et al., 1989; King et al.,
1989; Dati et al., 1991), implying the existence of mechanisms
regulating erbB-2 expression. One of these mechanisms may
be the expression of specific transcription factors. The OB2.1
factor, which footprints the human erbB-2 promoter, is
found in breast cancer cells that overexpress - but not in
those that do not - the erbB-2 gene (Hollywood & Hurst,
1993). Hormones may also play a role in the regulation of
erbB-2 expression and function. Oestrogens and EGF are
obvious candidates for such regulation, since oestrogen
receptor (ER) and erbB-2 or EGFR expression are inversely
correlated in breast carcinomas (Harris & Nicholson, 1988;
Perren, 1991). ER' tumours are generally well differentiated
and less invasive, whereas tumours overexpressing erbB-2
and/or EGFR are less differentiated and more aggressive.
We and other groups have demonstrated that 17p-oestra-
diol, which is strongly mitogenic for ER' breast cancer cells,
inhibits erbB-2 expression at both the mRNA and protein
level (Dati et al., 1990; Read et al., 1990; Warri et al., 1992).
In developing rat mammary gland tissues, p185e`bB-2 increases
progressively during pregnancy up to the complete functional
differentiation state (Dati et al., 1990). This can be repro-
duced in vitro using the mouse mammary epithelial cell line
HCI1, in which p185erbB-2 level increases on confluence and
during hormone-induced differentiation, whereas stimulation
ofcell growth by EGF is accompanied by down-regulation of
pl85erbB2 (Kornilova et al., 1992). The sum of these observa-
tions led us to ask whether erbB-2 down-regulation is a
general effect linked to the entry of mammary cells in the
replicative phase.
In the present study, we have compared the molecular
mechanisms by which 17P-oestradiol and EGF regulate erbB-
2 expression in ER' breast cancer cells. Treatment with
either EGF or oestradiol comparably stimulated growth and
concomitantly reduced p185erbB-2 level. However, oestrogen
treatment led to a repression of erbB-2 transcription, while
EGF was found to act primarily at the level of erbB-2
protein.
Materials and methods
Cell culture
ZR75.1 cells were obtained from the American Type Culture
Collection. The oestrogen-responsive T47D cell line was
obtained from Dr Salomon (Bethesda). Cells were main-
tained at 37°C with a 5% carbon dioxide atmosphere, in
Dulbecco's modified Eagle medium (DMEM) containing 5%
(T47D) or 10% (ZR75.1) heat-inactivated fetal calf serum
(FCS), 4 mM L-glutamine, 20 mM N-(2-hydroxyethyl) piper-
azine-N'-(ethanesulphonic acid) (HEPES) buffer pH7.4,
50 IU ml' penicillin and streptomycin. This medium is
designated 'complete medium' (CM). A medium devoid of
oestrogenic activity (SM) was prepared by adding 5%
dextran-coated charcoal (DCC)-treated FCS to Eagle
minimum essential medium with no phenol red, and other
supplements as in CM. Treatments were done with 17p-
oestradiol from a stock solution in ethanol (maximum
ethanol concentration in media 0.001%). The epidermal
growth factor was human recombinant EGF (Sigma), used at
10 ng ml-' unless otherwise specified, except for autokinase
experiments, in which mouse submaxillary gland EGF was
used at 400ng ml-'.
Immunoblotting analysis ofp185erbB-2
The anti-p185erbB2 antibodies were a 21N polyclonal anti-
serum, raised against the cytoplasmatic C-terminal peptide of
human pl85erbB2 (Gullick et al., 1987), used at 1:500, and the
OD3 monoclonal antibody, purchased from Applied Bio-
technology (Cambridge, MA, USA), directed towards the
external domain of human p185erbB-2. Cell pellets were lysed
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on ice in lysis buffer [20 mM Tris, pH 7.4, 0.1 M sodium
chloride, 5 mM magnesium chloride, 1% Nonidet P40, 0.5%
sodium deoxycholate, 0.1 mM DTT, 2 IU ml-' Trasylol and
1 mM phenyl methylsulphonyl fluoride (PMSF)]. Lysates were
centrifuged at 800g for 20 min at 4°C and stored at - 80°C.
Aliquots of 40-75 1tg of total proteins were electrophoresed
through 8% polyacrylamide (PAA) slab gels containing 0.1%
sodium dodecyl sulphate (SDS) and transferred to nitrocel-
lulose or PVDF filters. After saturation in 3% bovine serum
albumin (BSA) in NTEN [50 mM Tris, pH 7.4, 0.15 M
sodium chloride, 2 mM disodium ethylenediaminetetraacetate
(EDTA), 0.1% Nonidet P40] for 3 h at 37°C, filters were
incubated overnight at 4°C with the primary antibody in 3%
BSA-NTEN, then washed for 10 min in NTEN twice,
incubated for 1 h at room temperature in 3% BSA-NTEN
containing 0.1 tCi ml-l ['25I]protein A, washed again and
exposed to Hyperfilm MP autoradiographic films (Amer-
sham), at - 80°C for 4 days. For some experiments, blots
were revealed using the ECL chemiluminescence kit (Amer-
sham), following the manufacturer's protocol.
Northern blot assay
Total RNA was extracted either by the guanidine-lithium
chloride method, as described by Dati et al. (1990) or by the
AGPC procedure (Chomczynski & Sacchi, 1987), with minor
modifications. Aliquots of 10-20fig of total RNA were elec-
trophoresed on 1.2% agarose-formaldehyde denaturing gels,
transferred on Hybond N filters and UV fixed. Hybridisation
was done at 42°C overnight in 50% formamide, 5 x SSPE,
0.5% SDS, 5 x Denhart's, 20fgml-' calf thymus DNA, 8%
dextran sulphate and 1-2 x 106 c.p.m. ml-' random priming
32P-labelled probes. Stringency wash was done at 65°C for
30 min in 0.1 x SSC, 0.1% SDS; filters were exposed to
Hyperfilm MP films at - 80°C for 2-4 days. The erbB-2
probe was a 1.1 kbp BamHI fragment from the human c-
erbB-2 pCER204 cDNA (Yamamoto et al., 1986). Loading
and quality control was provided by three methods: (i)
ethidium bromide staining of the gels; (ii) filter staining with
methylene blue; (iii) filter rehybridisation to P-actin and
glyceraldehyde phosphate dehydrogenase (GAPDH) pro-
bes.
RNA elongation assay
Run-on assays were carried out essentially as previously de-
scribed (Greenberg et al., 1986). Cells were homogenised in
Dounce in buffer H (0.25 M sucrose, 10 mM magnesium
chloride, 2 mM DTT, 0.1% Nonidet P40 and 10mM HEPES,
pH 8.0) on ice. Lysate was centrifuged at 600g for 5 min and
the pellet washed once:- The pellet was resuspended gently in
buffer H containing 1 M sucrose, and centrifuged as above.
Nuclei were finally resuspended in buffer F [40% glycerol,
5 mM magnesium chloride, 0.1 mM EDTA, 2 mM dithioth-
reitol (DTT), 50 mM HEPES pH 8.0] and frozen in liquid
nitrogen. For the labelling reaction, 200 il of nuclei was
added to 200 il of solution R (1 mM each ATP, CTP, GTP,
5 mM magnesium chloride, 0.3 mM potassium chloride,
10 mM Tris pH 8.0) and 100tiCi [a-32P]UTP. Elongation was
allowed for 30 min at 30°C. Reacted nuclei were added at
40fig of yeast tRNA as carrier, then treated with 70 UI of
DNAse I and 50fig of proteinase K for 20 min at 37°C, and
lysed by addition of 15 mm EDTA and 0.5% SDS, with an
additional 20 min at 37°C. RNA was phenol-chloroform ex-
tracted and ethanol precipitated. Digestions, extraction and
precipitation were repeated once. After chloroform extrac-
tion, RNA were treated for 10 min on ice with 0.15 M
sodium hydroxide, neutralised and finally resuspended in
5 mM DTT containing 0.8 U ml-' RNAsin. Approximately
1 x I07 c.p.m. ofincorporated radioactivity was hybridised to
nitrocellulose strips to which 20 Mg of the appropriate
linearised and denatured plasmids had been transferred with
a slot-blot apparatus. Hybridisation was done at 42°C in
50% formamide for 60 h. Strips were washed twice for
30 min in 2 x SSC at 65°C, then digested with 10,.gml-'
RNAse A for 30min at 37°C, washed again in 2 x SSC,
0.1% SDS, for 1 h at 37°C and finally exposed to Kodak
XAR films for 3-10 days at - 80°C. Probes used were
human erbB-2 cDNA in two different vectors, pSV2 and
pLTR (DiFiore et al., 1987), the human c-MYC fragment
pRyc7.4 (Nishikura et al., 1983), the ribosomal protein rpL7a
cDNA, obtained from Dr S. Kozma (FMI, Basle, Switzer-
land) and sheared total genomic DNA from human placenta.
Reporterplasmids and chloramphenicol acetyl transferase
(CAT) assay
The human erbB-2 promoter fragment was derived from a
genomic clone spanning more than 8 kbp on the 5' end of the
gene. Cloning and characterisation of this clone, as well as
construction of CAT reporter vectors, are to be published
elsewhere. Part of the clone was sequenced and found to
correspond to the erbB-2 promoter sequence previously pub-
lished (Hudson et al., 1990). The construct used here
(pE2P.PP.CAT) was composed of a 219 bp fragment, extend-
ing from the PstI site, located at position -397, to the major
and most proximal transcriptional starting site, located at
position - 178, relative to the initiator codon ATG (Tal et
al., 1987). Here, a BamHI site was introduced to allow
cloning between the PstI and BamHI sites of plasmid
pBLCAT3 (Luckow & Schutz, 1987). A human ER expres-
sion vector (pHEO) was obtained from Dr Chambon, Stras-
bourg, France (Green et al., 1986). Transient transfections
were performed with 151g of pE2P.PP.CAT and 2jig of
pHEO, by the standard calcium-phosphate co-precipitation
procedure. As a control for promoter specificity, parallel
experiments were run with pRSV.CAT (Gorman et al., 1982).
Treatments were directly included in the medium used for
transfections and renewed after 24 h. Cells were harvested
40 h after transfection by scraping on ice in PBS. Evaluation
of CAT activity was performed by the thin-layer chromatog-
raphy (TLC) method as previously described (Sambrook et
al., 1989). Individual spots were cut and P-counted. A control
for transfection efficiency was provided by co-transfecting
3lsg of the P-galactosidase expression vector pCHI 10. p-
Galactosidase was evaluated in cell lysates by the colourimet-
ric method (Sambrook et al., 1989).
In vitro kinase assay
T47D cells were lysed in PT buffer [50 mM Tris-HCI
(pH 7.5), 5 mM EDTA, 50 mM sodium ethylene glycol-bis(b-
aminoethyl ether)N,N,N',NY,-tetracetate (EGTA), 1% Triton
X-100, 150 mM sodium chloride, 3 mM PMSF, 8 mgml'
aprotinin, 50 tLg ml-' leupeptin, 4mgml-' pepstatin, 1 mM
sodium orthovanadate, 20 mM phenyl arsine oxide] and cen-
trifuged at 12,000g for 10 min. pl85erbB-2 was
immunoprecipitated with the FRP5 MAb, which recognises
an epitope on the external domain of the human erbB-2
protein (Harwerth et al., 1992). Immunocomplexes were col-
lected with anti-mouse IgG-coated protein A-Sepharose,
washed and incubated with kinase buffer (20 mM HEPES,
pH 7.5, 10 mM magnesium chloride, 10 mM manganese
chloride, 0.1% Triton X-100, 0.1 mM sodium orthovanadate),
1OmCi of ['y-32P]ATP and 10 mM ATP for 15 min at room
temperature. Beads were washed, boiled in loading buffer for
5 min and proteins resolved on 8% polyacrylamide (PAA)
gels. The autophosphorylation of pl85erbB-2 was quantitated
using a phosphoimager.
Tyrosinephosphorylation assay
Cells were lysed on ice in PT buffer containing 20 mM
sodium molybdate and 20 mM sodium fluoride and the lysate
cleared by centrifugation at 2,000g for Omin at 4°C.
pl85erbB-2 was immunoprecipitated at 4°C with the 21N
antiserum and collected on protein G-Sepharose. Beads were
washed in ice-cold PT buffer, boiled for 5 min in SDS-PAGE
buffer, the denatured proteins resolved on 8% PAA gels and
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the 4G10 anti-phosphotyrosine MAb (UBI) and revealed by
the ECL method as described above. To provide a control
for the amount ofp185 in the lysate, filters were stripped and
reprobed with the 21N antiserum.
Results
Effects ofoestrogen and EGF on erbB-2 mRNA andprotein
expression
The effects of oestrogen and EGF on erbB-2 expression were
studied using the two ER' breast cancer cell lines T47D and
ZR75.1, in which erbB-2 expression and regulation was previ-
ously characterised (Dati et al., 1990; Antoniotti et al., 1992;
Taverna et al., 1994). T47D and ZR75.1 express moderate
levels of both pl85ebB-2 and EGFR as compared with other
breast cancer cell lines. They show 5- to 10-fold less pl85erbB-2
than cells with amplified erbB-2, such as SKBR.3 (Kraus et
al., 1988; Hynes et al., 1989) and express 5-10 x I03 EGFR
sites per cell (Koga et al., 1990; M. De Bortoli, unpublished
results). Moreover, they show comparable sensitivity to 17p-
oestradiol in terms of cell growth.
The effects of 17p-oestradiol or EGF treatment on the
expression oferbB-2 mRNA andp185erll-2 were evaluated by,
respectively, Northern and Western blotting. Figure 1 shows
a comparison between the levels of pl85elbB-2 and of erbB-2
mRNA in ZR75.1 cells after 2 days of treatment with the
effectors. In these conditions, cell growth in the presence of
17p-oestradiol and EGF was, respectively, 281 ± 64% and
216 ± 108% of the growth in the absence of the factors, as
determined by direct counting of viable cells. Both 17,-
oestradiol and EGF induced a dramatic decrease in pl85erbB2.
However, a parallel decrease in erbB-2 mRNA was observed
only in 17p-oestradiol-treated cells. EGF-treated cells con-
tained 30-40% more erbB-2 mRNA than control cells, as
determined by densitometric evaluation of the blots. Down-
regulation of p185er8B-2 by EGF was roughly equivalent
whether the treatment was carried out in complete medium
(CM) or in medium with charcoal-treated FCS (SM). The
effects of oestrogens on both growth and erbB-2 expression
are evidenced only when cells are cultured in SM, i.e. in the
absence of oestrogen. Culture of the cells in SM brings about
a progressive increase in erbB-2 protein level as well as
promoter activity during 2 weeks ofculture (Dati et al., 1990;
Taverna et al., 1994).
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Reprobing of the protein blots with the OD3 monoclonal
antibody, which recognises the external domain of human
p185erbB-2, gave similar results (not shown). This ruled out the
possibility that EGF effect might result from masking of the
C-terminus of pl85erbB2, the epitope recognised by the 21N
antibody used throughout this study.
The effects of 17P-oestradiol and EGF on pI85erbB-2 were
dose dependent. As shown in Figure 2, after culturing T47D
cells in SM for 4 days and treating for additional 4 days,
maximal effect was seen with 1 x 10-9M and 1 x 10-8M
17p-oestradiol; the EGF effect was clearly seen at concentra-
tions as low as 1 ngml', corresponding to 1.7 x 10-1"M.
These values are consistent with receptor-mediated effects:
the affinities of ER for 17p-oestradiol and of the EGFR for
EGF in T47D cells are respectively: Kd- 0.5 x 10' and
Kd-1 x 10-9 M (Koga et al., 1990; M. De Bortoli, unpub-
lished).
pl85erbB-2 down-regulation by both 17p-oestradiol and EGF
was relatively slow. Reduction ofp185erbB-2 was seen after 5 h
of treatment (Figure 2, right), but a time-course analysis
showed that the maximal response to both factors occurred
after 4-5 days of treatment (not shown). However, it is
important that cells do not reach confluence during this time,
since up-regulation of erbB-2 expression by cell confluence
takes place (Taverna et al., 1994). For this reason, in all the
experiments described here, conditions were set in order to
avoid reaching confluence degrees higher than 60-70%.
Similar dose and time dependence were measured on ZR75.1
cells (not shown).
EGF induces tyrosinephosphorylation ofpJ85`erbB2 in ER'
breast cancer cells
It has been reported that EGF induces pl85erbB-2 phos-
phorylation (King et al., 1988; Stern & Kamps, 1988). We
examined this in ER' breast cancer cells that express
moderate levels of both pl85erbB-2 and EGFR. First, we
studied the in vitro kinase activity ofpl85erbB-2 following EGF
treatment. Treatment of T47D cells with EGF at 37°C for
10min caused a 3.3-fold increase in the kinase activity that
co-immunoprecipitated with pl85erbB-2, as determined by
quantitation with a phosphoimager (Figure 3). A second,
lower band is visible in EGF-stimulated cells. Since
heterodimerisation of the EGFR with pl85erbB-2 has been
reported in SKBR3 breast cancer cells (Goldman et al.,
1990), this band may be due to co-immunoprecipitated
EGFR.
Tyrosine phosphorylation ofpl85erbB-2 after EGF treatment
of T47D cells was studied by blotting with an anti-
phosphotyrosine antibody. Immunoprecipitated p185erbB-2
from EGF-treated cells, but not from control cells, contained
phosphotyrosine, as shown in Figure 4. EGF-induced
pl85erbB-2 phosphorylation was transient, being maximal at
5 min and decreasing thereafter. Reprobing of the blot with
the 21N anti-pI85erbB-2 antibody provided a control for the
amount of p185erbB-2 in each lane (Figure 4, bottom). As in
Figure 3, the lower tyrosine-phosphorylated protein which
co-immunoprecipitated with p185erbB-2 may represent EGFR.
-Log[E21 C EGF ng ml-1 5 h
1_ m1 rIm I
erbB2
mRNA
p185
- E2 EGF
Figure 1 Immunoblotting analysis of pl85erbB2 and Northern
blot analysis of erbB-2 mRNA in ZR75.1 cells treated with
17j1-oestradiol or EGF. Approximately I x 106 cells were plated
in 10cm dishes and grown for 3 days in complete medium (CM),
then treated for 2 days in CM or stripped medium (SM) with
I x 10-8M I 17p-oestradiol or 10 ngml' EGF, as indicated.
Figure 2 Immunoblotting analysis of pl85ebB-2 level in T47D
cells treated with different concentrations of 17p-oestradiol and
EGF. Approximately 1.5 x 106 cells were plated in 10cm dishes
and grown in SM for 4 days, then treated as indicated in SM for
4 additional days. Right: Cells treated with 1 X 10-8 M 17p-
oestradiol or 10ng ml- EGF or nothing for 5 h.
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Figure 3 Kinase activity of pl85erbB-2 following EGF treatment
of T47D cells. Cells were preconditioned in 1% FCS-DMEM for
24 h, then treated or not with 400 ng ml-' mouse EGF for
10min at 37°C. pl85erbB-2 was immunoprecipitated with either a
preimmune (PI) or the FRP5 anti-p185erbB-2 monoclonal antibody
on anti-mouse IgG-coated protein A-Sepharose. Beads were
incubated with [y-32P]ATP for 10 min at room temperature, then
proteins were solubilised and separated on 8% polyac-
rylamide-SDS gels.
Similar results were obtained on ZR75.1 cells (not
shown).
When this work was in progress, it was reported that in
fibroblasts not expressing the ER and stably transfected with
human erbB-2 there was a rapid and transient activation of
pl85erbB-2 by 1 x 10-6 M 17P-oestradiol (Matsuda et al., 1993).
For this reason, we examined the effects of either a physio-
logical concentration (1 x 10-8M) or a non-physiological
concentration (1 x 106M) of 17p-oestradiol on erbB-2
tyrosine phosphorylation in T47D cells. Figure 4 shows that
a 10 min treatment with both doses of 17p-oestradiol led to a
slight increase in p185erbB-2 phosphotyrosine, as compared
with cells cultured in SM without oestrogens. The effect of
oestrogen was more than 10-fold less than that evoked by
EGF in similar conditions, These data demonstrate that in
ER' breast cancer cells with low levels of both receptors
EGF induces tyrosine phosphyorylation of pl85erbB-2, most
likely through its own receptor, while 17p-oestradiol, even at
very high concentration, does not lead to the same extent of
pl85erbB-2 phosphorylation as that induced by EGF.
Oestrogens inhibit erbB-2 expression at the transcriptional
level
We investigated whether the oestrogen effect on erbB-2
mRNA might be due to inhibition of erbB-2 gene transcrip-
c
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tion. The numbers of transcripts initiated in the presence and
in the absence of 17p-oestradiol by nuclei of ZR75.1 cells
were evaluated by a nuclear run-on assay. Figure 5 shows the
results obtained on cells treated with or without 17P-oes-
tradiol for 48 h. Quantitation of hybridised slots showed that
oestrogen-treated cells possess about 50% of the initiated
transcripts of erbB-2 compared with control cells. No change
in c-MYC gene transcription following oestrogen treatment
was seen, in keeping with the fact that long-term enhance-
ment ofc-MYC expression by oestrogen in breast cancer cells
is due to stabilisation of the c-MYC mRNA (Santos et al.,
1988). The effect of EGF on erbB-2 transcription was not
studied.
Since this experiment demonstrated transcriptional inhibi-
tion of erbB-2 by oestrogens, we asked whether the elements
mediating transcriptional repression were located within the
promoter of the erbB-2 gene or were located in more distal
regions of the gene. In fact, examination of the published
sequence of the first 1.2 kbp of the human erbB-2 promoter
(Hudson et al., 1990) did not reveal any oestrogen-responsive
consensus element. A CAT reporter plasmid, containing the
most proximal 219 bp fragment of the human erbB-2 pro-
moter, extending from the PstI site at - 397 to the major
transcriptional starting site at - 178 relative to the initiator
ATG, was derived from a human genomic clone. This con-
struct, called pE2P.PP.CAT, was transiently transfected in
T47D cells and expression of CAT after treatment with
17P-oestradiol and EGF evaluated.
In Figure 6 an example of CAT assay on T47D cells
treated with 17p-oestradiol or EGF is shown. Averaging
three independent transfections in the same conditions, and
normalising the activities on the basis of the co-transfected
,-galactosidase, it was possible to calculate a _60% repression
by 17i-oestradiol and a 4- to 5-fold stimulation by EGF.
Calculated values with standard deviations are shown in
Figure 6. In order to observe transcriptional repression by
17fr-oestradiol, it was necessary to co-transfect the ER ex-
pression plasmid pHE0. In its absence, the transcriptional
response was 3- to 4-fold less. No effects were seen on the
transcriptional activity of the control plasmid containing the
Rous sarcoma virus (RSV) long terminal repeat (LTR) driv-
170-Oestradiol
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Figure 4 Phosphotyrosine immunoblotting of T47D cells treated
or not with 100 ng ml ' EGF for the indicated time at 37°C or
with the indicated concentration of 17P-oestradiol for 10 min.
Approximately 1.5 x 106 cells were plated in 6 cm dishes, grown
in CM, then cultured for 24 h in medium containing 1% DCC-
stripped FCS prior to treatment. Bottom: Blot reprobed with the
anti-p185erbB-2 21N antibody.
Figure 5 Run-on analysis of transcripts initiated by ZR75.1 cells
in the presence or absence of 17p-oestradiol. Cells were grown in
SM and treatment with 1 x 10-8 M 17p-oestradiol performed for
48 h in SM. Nuclear transcript elongation was continued in vitro
in the presence of [a-32PJUTP and labelled RNA was then ex-
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intensity of GAPDH hybridisation. Figure 7 shows that
CHX itself, in the absence of oestrogen, decreased erbB-2
mRNA by 41% (compare lanes e and j). In 24 h, 17,-
oestradiol induced a 57% decrease in erbB-2 mRNA in the
absence, but not in the presence, of CHX (compare lanes
d-e and i-j). As a control for CHX efficacy, the blot was
rehybridised to a c-MYC probe. At 3 h, expression ofc-MYC
is transiently induced by 17p-oestradiol (lane a) and superin-
duced by CHX (lane f), as previously described (Greenberg et
al., 1986). Although ethidium bromide staining of the gel and
methylene blue staining of the filter revealed no significant
differences in the amount of RNA present in each lane,
minor differences were seen in both mRNAs used for com-
parison, i.e. P-actin and GAPDH. Evaluation of several
similar experiments, which gave similar results, allowed us to
conclude that inhibition of protein synthesis abolishes oestro-
genic repression of erbB-2.
171- Oestradiol in SM
EGF in SM
CM
EGF in CM
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0.115 ± 0.023
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Figure 6 Transcriptional activity of the erbB-2 promoter [-219;
+ 1]-CAT construct (E2P.PP.CAT) in transient transfection on
T47D cells. Cells were conditioned in SM for 24 h, then transfected
with E2P.PP.CAT plus the ER expression vector pHEO. Treatments
with 1 x 10 -8M m 17p-oestradiol in SM or 10 ng ml EGF, in either
SM or CM, were started just after DNA precipitate addition. The
picture shows one representative CAT assay. CAT activity values are
expressed as nmol h-' mg-' and were calculated averaging three
independent experiments.
ing the CAT gene. Similar results were obtained on ZR75.1
cells (data not shown).
Finally, we examined whether repression of erbB-2 by
oestrogen requires protein synthesis. This question was
justified by both the absence of an oestrogen response ele-
ment in the oestrogen-repressible fragment of the erbB-2
promoter and by the relatively slow kinetics of oestrogen
action. ZR75.1 cells precultured in SM for 4 days were
treated with 17P-oestradiol for 3, 6, 12 and 24 h in the
presence or absence of cycloheximide (CHX) and the levels
of erbB-2 mRNA measured by Northern blotting. Semiquan-
titative estimation of erbB-2 mRNA was made by computer-
assisted image analysis. Values were corrected on the
CHX + + + + +
170-Oestradiol + + + +
H
GA
+ + + +
Figure 7 Northern blot analysis of erbB-2 mRNA in ZR75.1 cells
treated or not with 1 x 10-8 M 17P-oestradiol in the presence of
absence ofcycloheximide. Approximately 3 x 106 cells were plated in
T150 flasks and grown in SM for 4 days, then treated as indicated.
Cycloheximide (50 1M) was added I h before adding 17p-
oestradiol.
Discussion
This study shows that oestrogen and EGF, two agents which
stimulate growth of ER' human breast cancer cells, cause a
down-regulation of pl85e"bB.2. The mechanisms leading to a
decrease in p185erbB-2 differ. Despite the fact that EGF has a
positive effect upon erbB-2 mRNA levels, its effects upon the
kinase activity and tyrosine phosphorylation of pl85erbB-2 lead
to decreased protein levels. Conversely, p185erbB-2 down-
regulation by oestrogens is accompanied by a parallel
decrease in erbB-2 mRNA, transcription rate and promoter
activity. It is known that EGF can induce pl85ebB-2 phos-
phorylation on tyrosine (Stern & Kamps, 1988; King et al.,
1988). The mechanism of transphosphorylation involves
receptor heterodimerisation (Wada et al., 1990) and
heterodimers of pl85erbB-2 and EGFR have been detected in
the SKBR.3 breast cancer cells, which carry several copies of
the erbB-2 gene and express high levels of p185erbB-2 (Gold-
man et al., 1990). Heterodimeric forms have higher affinity
for EGF than EGFR homodimers and possibly activate
separate transduction pathways (Wada et al., 1990). It is
likely that heterodimerisation of EGFR and pl85erbB-2 also
takes place in T47D cells, since in the in vitro kinase assays
and in the phosphotyrosine blot a second band of lower
molecular weight is visible, indicating the coimmunopre-
cipitation, with p 85erbB2, ofa phosphorylated _ 170 kDa pro-
tein. In these cells it was not possible to obtain direct
evidence of heterodimer formation, probably because of the
low level of expression of both receptors. EGF treatment of
HC11 mouse mammary cells led to a down-regulation of
p185erbB-2, by increasing its phosphorylation and accelerating
the rate of its internalisation and degradation (Kornilova et
al., 1992). It is possible that in T47D cells a similar
mechanism takes place. Further studies may elucidate this
possibility.
We noticed a slight positive effect of EGF on the steady-
state erbB-2 mRNA level and a strong positive effect on
erbB-2 promoter activity in T47D cells. EGF has also been
shown to stimulate an erbB-2 promoter-luciferase reporter
gene in HeLa cells (Hudson et al., 1990). The effect of EGF
on erbB-2 promoter activity is much stronger than its effect
on the steady-state level of erbB-2 mRNA. This may reflect
either post-transcriptional regulation or the presence of more
distal repressors in the erbB-2 regulatory sequences. Indeed,
an erbB-2 promoter construct extending to position - 1,398
showed a very small response to EGF in both transient
transfection on T47D and in stable T47D transfectants
(Taverna et al., 1994). Studies are under way to localise the
element(s) modulating these transcriptional responses to EGF
in mammary cells.
Down-regulation oferbB-2 by oestrogens appears generally
stronger at the protein level than at the mRNA level, a
finding noted by others (Russel & Hung, 1992). In the
experiments reported here we observed a 50-70% inhibition
of erbB-2 transcriptional activity, which appears lower than
the decrease in p185er`R-2 seen in immunoblots. As mentioned
c-
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above, a rapid activation ofpl85erbB-2 kinase by high concen-
trations of 17p-oestradiol, was observed in ER- mouse fibro-
blasts expressing high levels of human erbB-2 (Matsuda et
al., 1993). The authors suggest that 17P-oestradiol may
directly bind to pl85erbB-2, leading to an increase in its kinase
activity and its internalisation. These provocative findings
await further experimental proof. However, a rapid and tran-
sient ER-dependent increase in the phosphotyrosine content
of several cellular proteins, following oestrogen treatment of
MCF7 breast cancer cells has also been reported (Migliaccio
et al., 1993). Our data show that the extent of pl85erbB-2
tyrosine phosphorylation induced by oestrogens in T47D
cells is slight, yet it may account for the different amplitude
of response to oestrogens observed between erbB-2 protein
and mRNA or transcription.
Oestrogens clearly inhibit erbB-2 expression at the tran-
scriptional level. Oestrogen decreased both the number of
erbB-2 transcripts which can be elongated in vitro and tran-
scription of the human erbB-2 promoter-CAT reporter gene.
The degree of such inhibition is probably dependent upon the
level of ER present in the cell, since co-transfecting an ER
expression vector resulted in a much larger transcriptional
repression (50-70% vs 20-30%). However, the endogenous
ER present in T47D cells is sufficient to mediate a 60%
repression of a stably integrated 1.2 kbp erbB-2 pro-
moter-CAT construct (Taverna et al., 1994).
Transcriptional repression of the rat NEU gene by
oestrogen-activated ER has been reported (Russel & Hung,
1992). The responsive region is contained within a 144bp
fragment near, but not contiguous, to the transcriptional
starting sites. The promoters of rat NEU and human erbB-2
are nearly identical in their proximal portion (White & Hung,
1992); the oestrogen-repressible rat NEU 144 bp fragment
corresponds to positions -354 to -210 ofthe human erbB-2
promoter, and thus it is contained entirely in the construct
used here. Importantly, this fragment contains the two most
proximal of the three footprints revealed in T47D and ZR75.1
cells (Hollywood & Hurst, 1993). Sequence analysis of this
fragment reveals several potential regulatory elements, includ-
ing OTFI, MYB, Spl, K-enhancer, which are contained in the
footprinted sequences. In addition, this fragment was shown to
be repressed by the MYC and ElA oncogenes (Suen & Hung,
1991). Repression of erbB-2 promoter-CAT constructs by co-
transfection of a c-MYB expression vector has also been
observed (P. Maggiora et al., in preparation). Both c-MYC
and c-MYB expression is stimulated by oestrogens in breast
cancer cells (Santos et al., 1988; Dati et al., 1990; Collyn
d'Hooge et al., 1991), which leads to the hypothesis that the
c-myc and/or c-myb proteins may mediate the oestrogen-
induced repression of erbB-2 transcription.
The question of whether oestrogen may require protein
synthesis to inhibit erbB-2 was approached by using cyclo-
heximide. It must be emphasised that, given the slow kinetics
of erbB-2 regulation and the short half-life of the oestrogen
receptor (see below), it is extremely difficult to interpret these
results. As already mentioned, during the growth of T47D or
ZR75.1 cells in SM, i.e. in medium deprived of steroids, the
expression of both erbB-2 mRNA and pl85erbB-2 increases for
several days (Dati et al., 1990; Read et al., 1990; Russel &
Hung, 1992; Taverna et al., 1994). The treatment with CHX
indeed blocked not only the inhibitory effect of oestrogen but
also the increase in erbB-2 expression in SM. One explana-
tion for this is that the increasing expression of erbB-2 in SM
may reflect an increased synthesis of trans-activator(s), and
that inhibition of erbB-2 expression by oestrogen may be due
to trans-repressor(s) synthesis, e.g. c-MYB or c-MYC, as
discussed above. However, it is clear that, in the absence of
protein synthesis, the amount of oestrogen receptor itself is
significantly reduced, as a half-life of 3-5 h has been re-
ported in MCF7 breast cancer cells in either the presence or
absence of oestrogens (Eckert et al., 1984). Reduction of
oestrogen response by CHX may then simply reflect the
progressive disappearance of oestrogen receptor. Direct
repression of gene expression by members of the steroid
receptor family may be exerted through titration of positive
co-factors or by competition with positive factors (for review,
see Beato, 1991). Such a mechanism would be compatible
with our observations. Further studies are under way to
understand the exact molecular mechanism of erbB-2 repres-
sion by oestrogen.
In conclusion, the data presented here show that there is
an important difference between oestrogen- and EGF-stimu-
lated breast cancer cell growth. Since oestrogens lead to a
loss of p185erbB-2, signal transduction through p185erbB-2
homodimers or heterodimers with other members of the
EGFR family is abrogated. In contrast, EGF treatment leads
to the activation of pl85ebB-2. These differences may be very
significant and partially explain the different behaviour of
ER' and EGFR+ breast tumours.
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